Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

PROCEPT BioRobotics (PRCT) EBITDA (2020 - 2026)

PROCEPT BioRobotics has reported EBITDA over the past 7 years, most recently at -$31.7 million for Q1 2026.

  • Quarterly EBITDA fell 28.69% to -$31.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$102.7 million through Mar 2026, down 14.02% year-over-year, with the annual reading at -$95.6 million for FY2025, 4.67% down from the prior year.
  • EBITDA was -$31.7 million for Q1 2026 at PROCEPT BioRobotics, down from -$29.8 million in the prior quarter.
  • Over five years, EBITDA peaked at -$17.2 million in Q1 2022 and troughed at -$31.7 million in Q1 2026.
  • The 5-year median for EBITDA is -$24.6 million (2025), against an average of -$24.2 million.
  • Year-over-year, EBITDA tumbled 65.64% in 2023 and then skyrocketed 31.7% in 2024.
  • A 5-year view of EBITDA shows it stood at -$28.4 million in 2022, then rose by 3.45% to -$27.4 million in 2023, then surged by 31.7% to -$18.7 million in 2024, then plummeted by 59.42% to -$29.8 million in 2025, then decreased by 6.18% to -$31.7 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's EBITDA are -$31.7 million (Q1 2026), -$29.8 million (Q4 2025), and -$21.2 million (Q3 2025).